C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer
The pre-treatment CALLY index represents a readily available biomarker that independently predicts BCR and may complement established risk stratification tools in prostate cancer, although model performance was modest. External validation in prospective cohorts with longer followup is necessary before clinical implementation.
Authors
- Mert Başaranoğlu (ORCID: https://orcid.org/0000-0002-9873-4920)
- Ahmet Karakeçi (ORCID: https://orcid.org/0000-0003-2097-9853)
- Mustafa Sesli (ORCID: https://orcid.org/0000-0001-5200-698X)
- Ahmet Alper Özdeş (ORCID: https://orcid.org/0009-0008-3745-1880)
- İrfan Orhan
- Erdem Akbay
Institutions
- Sivas State Hospital (TR)
- Malatya Devlet Hastanesi (TR)
- Yeditepe University Hospital (TR)
- Mersin Üniversitesi (TR)
Publication Details
- Journal
- Canadian Urological Association Journal
- Published
- 2026-03-16
- DOI
- https://doi.org/10.5489/cuaj.9414
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00